Old Web
English
Sign In
Acemap
>
authorDetail
>
Hans Holger Fischer
Hans Holger Fischer
Trastuzumab
Paclitaxel
Pertuzumab
Medicine
Biomarker (medicine)
2
Papers
10
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (2)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
De-escalated neoadjuvant pertuzumab+trastuzumab with or without paclitaxel weekly in HR-/HER2+ early breast cancer: ADAPT-HR-/HER2+ biomarker and survival results.
2021
Journal of Clinical Oncology
Nadia Harbeck
Oleg Gluz
Matthias Christgen
S. Kuemmel
Eva Maria Grischke
Michael Braun
Jochem Potenberg
Katja Krauss
Claudia Schumacher
Helmut Forstbauer
Toralf Reimer
Andrea Stefek
Hans Holger Fischer
E. Pelz
M. Graeser
Christine Eulenburg
Ronald E. Kates
Rachel Wuerstlein
Hans Kreipe
Ulrike Nitz
Show All
Source
Cite
Save
Citations (3)
Final analysis of WSG-ADAPT HER2+/HR- trial: Efficacy, safety, and predictive markers for 12-weeks of neoadjuvant dual blockade with trastuzumab + pertuzumab {+/-} weekly paclitaxel in HER2+/HR- early breast cancer (EBC).
2016
Journal of Clinical Oncology
Ulrike Nitz
Oleg Gluz
Matthias Christgen
Eva Maria Grischke
D Augustin
Sherko Kümmel
Michael Braun
Jochem Potenberg
Andreas Kohls
Katja Krauss
Andrea Stefek
C Schumacher
Helmut Forstbauer
Toralf Reimer
Hans Holger Fischer
Cornelia Liedtke
Rachel Wuerstlein
Hans Kreipe
Nadia Harbeck
Show All
Source
Cite
Save
Citations (7)
1